TY - JOUR
T1 - Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism
AU - Martínez-Urbistondo, Diego
AU - de la Garza, Rocío G
AU - Villares-Fernández, Paula
AU - Font, Carme
AU - Schellong, Sebastian
AU - López-Núñez, Juan José
AU - Gil-Díaz, Aída
AU - Del Carmen Díaz-Pedroche, María
AU - Hirmerova, Jana
AU - Monreal, Manuel
AU - RIETE Investigators
A2 - Skride, Andris
N1 - © 2021. Società Italiana di Medicina Interna (SIMI).
Full list of RIETE Investigators is provided at the end of the article.
PY - 2021/10/9
Y1 - 2021/10/9
N2 - The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10-2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04-2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation.
AB - The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10-2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04-2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation.
UR - http://www.scopus.com/inward/record.url?scp=85116816148&partnerID=8YFLogxK
U2 - 10.1007/s11739-021-02858-x
DO - 10.1007/s11739-021-02858-x
M3 - Article
C2 - 34626318
JO - Internal and Emergency Medicine
JF - Internal and Emergency Medicine
SN - 1828-0447
ER -